Positive Press Coverage Somewhat Unlikely to Affect Medifast (MED) Share Price
Media stories about Medifast (NYSE:MED) have been trending positive this week, Accern Sentiment reports. Accern identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Medifast earned a news impact score of 0.31 on Accern’s scale. Accern also gave news articles about the specialty retailer an impact score of 45.8675073944565 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Simply Good Foods (SMPL) versus Medifast (MED) Critical Review (americanbankingnews.com)
- Contrasting Simply Good Foods (SMPL) & Medifast (MED) (americanbankingnews.com)
- Medifast (MED) and Simply Good Foods (SMPL) Financial Review (americanbankingnews.com)
- Analyzing Medifast (MED) & Simply Good Foods (SMPL) (americanbankingnews.com)
Shares of Medifast (MED) opened at $68.71 on Thursday. The firm has a market cap of $819.96, a PE ratio of 33.68, a price-to-earnings-growth ratio of 1.80 and a beta of 0.50. Medifast has a 52 week low of $40.00 and a 52 week high of $74.78.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 8th. Shareholders of record on Friday, December 22nd will be paid a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a yield of 2.79%. This is a boost from Medifast’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, December 21st. Medifast’s dividend payout ratio is currently 94.12%.
MED has been the subject of several recent research reports. Zacks Investment Research raised shares of Medifast from a “hold” rating to a “buy” rating and set a $81.00 price target for the company in a research report on Saturday, January 13th. ValuEngine lowered shares of Medifast from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, DA Davidson increased their price target on shares of Medifast to $89.00 and gave the stock a “buy” rating in a research report on Friday, December 8th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Medifast currently has an average rating of “Hold” and a consensus price target of $75.00.
In other Medifast news, Director Glenn W. Welling sold 250,000 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $65.00, for a total transaction of $16,250,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Glenn W. Welling sold 275,000 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $64.60, for a total transaction of $17,765,000.00. The disclosure for this sale can be found here. 5.40% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This report was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.watchlistnews.com/positive-press-coverage-somewhat-unlikely-to-affect-medifast-med-share-price/1836020.html.
Medifast, Inc produces, distributes and sells weight loss, weight management, and healthy living products, and other consumable health and nutritional products. The Company’s product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products, and vitamins.
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.